Navigation Links
Intarcia Therapeutics Announces Presentation of Final Results From,a Phase 2 Combination Study for the Treatment of Hepatitis C at the,Digestive Disease Week Conference

ontinuous release formulation of omega interferon with the Omega DUROS device may improve the treatment of HCV by offering a more convenient, potentially safer and more efficacious therapy for HCV patients."

About Omega DUROS Therapy

Omega DUROS therapy is being developed to improve the treatment of HCV by offering a more convenient and potentially safer and more effective treatment. Omega DUROS therapy is designed to deliver a continuous and consistent dose of omega interferon for three months via the implantable DUROS device, a drug delivery technology developed by ALZA Corporation, and licensed to Intarcia for use in certain broad fields. Another product incorporating the DUROS technology has already been approved by the FDA for the palliative treatment of prostate cancer. Intarcia is also leveraging the DUROS technology in evaluating other drug development opportunities. The most advanced of these is focused on the delivery of GLP-1 and GLP-1 analogs with the DUROS device for the treatment of type 2 diabetes.

About Intarcia

Intarcia Therapeutics, Inc. is a biopharmaceutical company developing therapeutics for patients with chronic diseases in which there are significant unmet medical needs. Intarcia's drug development expertise and competitive edge are complemented by its ability to stabilize macromolecules and to deliver them in a constant and consistent manner via the proprietary DUROS drug delivery platform. The initial programs that Intarcia is pursuing are in hepatitis C and type 2 diabetes.

About Hepatitis C

Hepatitis C is a major global public health problem. According to the World Health Organization, more than 170 million people worldwide are chronically infected with HCV, and three to four million new HCV infections occur annually. The U.S. Centers for Disease Control and Prevention has estimated that in the United States approximately 3.2 million people are chronically infected with HCV and approximately 25,00
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Intarcia Therapeutics Announces Final Results From a Phase 2 Study of Injectable Omega Interferon plus Ribavirin for the Treatment of Hepatitis C Genotype-1
2. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
3. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
4. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
5. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
6. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
7. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
8. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
9. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
10. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
11. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
Post Your Comments:
(Date:5/16/2008)...nd customer thought leaders -, SAN FRANCISCO, May...ader and trusted resource for clinical trial manag...prestigious academic medical centers, research,ins... group meeting in San,Francisco. The Velos eResear...boratively manage thousands of clinical trials., ...
(Date:5/16/2008)...r PEGylation of a Small Molecule with ...OS, Calif., May 16 /- Nekta...results today from a Phase 1,study of NKTR- 102, P...ti-tumor activity in patients with refractory soli...s small molecule PEGylation technology,produced an...
(Date:5/16/2008)... Significant Reductions in Selected ...ublished in 2008 Proceedings of the American Socie... SAN DIEGO, May 16 /- ADVE... today that, in a registrational bioequivalence,cl... significant reduction,in general disorders and ad...
(Date:5/15/2008)...FirstCall/ -- Medivation, Inc.,(Nasdaq: MDVN ) to...clinical,trial of its novel androgen receptor anta...entation at the 44th American Society of Clinical ...sion title: New Targeted Strategies for Patients w..., June 2 at 11:30 a.m. Central Time Abstract titl...
Breaking Medicine Technology:Top Academic Medical Centers, Research Institutions, and Partners Gather, Share Experiences and Success Stories at Velos eResearch Annual Meeting 2Top Academic Medical Centers, Research Institutions, and Partners Gather, Share Experiences and Success Stories at Velos eResearch Annual Meeting 3Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 2Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 3Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 4Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 5ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study 2ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study 3ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study 4ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study 5Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting 2Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting 3PEAK Surgical Announces Positive Surgical Incision Wound Healing Results With the PEAK PlasmaBlade 28TM 29 3260 1PEAK Surgical Announces Positive Surgical Incision Wound Healing Results With the PEAK PlasmaBlade 28TM 29 3260 2PEAK Surgical Announces Positive Surgical Incision Wound Healing Results With the PEAK PlasmaBlade 28TM 29 3260 3 2437 million financing for company based on macular degeneration research 3256 1 2437 million financing for company based on macular degeneration research 3256 2Lunch Lady Challenges Schools Families to Make Kids Nutrition a Priority 3251 1Lunch Lady Challenges Schools Families to Make Kids Nutrition a Priority 3251 2Angel Flight West Recognizes Southern California Pilots at 24th Anniversary 3246 1Angel Flight West Recognizes Southern California Pilots at 24th Anniversary 3246 2
(Date:5/16/2008)...EWPORT BEACH, Calif., May 16 /PRNewswire-FirstCall...P ) announced today the promotion of David,M. Boit... Officer. "Dave,has made a tremendous contribution...y our strong investment growth and diversification... over $1 billion in accretive,investments for NHP,...
(Date:5/16/2008)...AN DIEGO, May 16 /PRNewswire-FirstCall/ -- CryoCor...cused on the treatment of cardiac,arrhythmias, ann...ers of,CryoCor common stock filed a complaint in t...ty of San Diego, naming as defendants each member ...Boston Scientific Corporation.,The complaint is st...
(Date:5/16/2008)...ment guidelines quickly disseminated to community ...16 (HealthDay News) -- Partnerships between major ...e a quick and effective way to spread cancer treat... Center in Philadelphia. , Most new cancer trea...ost cancer care is provided at community hospitals...
(Date:5/16/2008)...ismatch in some early stage cases makes therapy of...RIDAY, May 16 (HealthDay News) -- Colon cancer pat...need to receive chemotherapy. In fact, not only do..., it may actually harm them, a new study found. ,...ncer], then you should not be treated with chemoth...
Breaking Medicine News(10 mins):Health News:David M. Boitano Promoted to Senior Vice President 2Health News:CryoCor, Inc. Subject of Lawsuit Relating to Tender Offer and Merger 2Health News:CryoCor, Inc. Subject of Lawsuit Relating to Tender Offer and Merger 3Health News:CryoCor, Inc. Subject of Lawsuit Relating to Tender Offer and Merger 4Health News:Partnerships Effective Communicators of Cancer Advances 2Health News:Not All Colon Cancer Patients Need Chemotherapy: Study 2
...eening system combining digital photography with I...method to screen for a common childhood oral disea...ty toddlers. Early childhood dental caries (ECC... tooth decay, results from prolonged exposure to s...
...study published in the journal, Cell Metabolism, r...ion in the zebrafish that are remarkably similar t...es disease that could aid in finding new therapies...ead to the aquarium fish becoming an important ani...
... mothers may someday get a personalized menu of fo...netic makeup as a result of new research at Washin... Researchers used transparent fish embryos to dev...genes and diet interact to cause birth defects. "...
...can children with asthma make more clinic visits t... severity.// Asthma has been on the rise for the ... especially high prevalence. A study in the August...hat Puerto Rican children with asthma make more cl...
Other Medicine News:Health News:New Screening System For Early Detection Of Dental Caries in Toddlers 2Health News:New Screening System For Early Detection Of Dental Caries in Toddlers 3Health News:New Studies On Zebrafish Could Aid in Treating Birth Defects 2Health News:New Studies On Zebrafish Could Aid in Treating Birth Defects 3Health News:New Studies On Zebrafish Could Aid in Treating Birth Defects 4Health News:Unmasking Nutrition's Role in Genes and Birth Defects 2Health News:Unmasking Nutrition's Role in Genes and Birth Defects 3Health News:Children of Different Race Show Different Patterns of Asthma Care 2
Self retaining brain retractor.
The Budde Halo brain retractor is designed for use in all intercranial procedures where retraction of delicate brain tissue is required.
Langenbeck periosteal elevators, wide, blade width 11/16" (17 mm), length 7 1/2" (191 mm).
Cushing periosteal elevators, Gutsch handle, sharp, narrow, blade width 3/16" (5 mm), length 7 5/8" (194 mm).
Medicine Products: